Search

Dorit Ron

from San Francisco, CA
Age ~65
Get Report
Also known as:
Ron Dorit, Ron Doorit
Phone and address:
310 Sanchez St, San Francisco, CA 94114
(415) 503-1415
Related to:
Ron Dorit
Connected to:
Alexis J Ron, 77Carmen A Ron, 58Gordon Ron, 45Jay Ron, 58Justin G Ron, 30Miguel M Ron, 48Natalia Ron, 43Shlomo Ron, 80Tiny Ron, 76Tom H Ron, 36

Dorit Ron Phones & Addresses

  • 310 Sanchez St, San Francisco, CA 94114 (415) 503-1415
  • San Diego, CA
  • 310 Sanchez St, San Francisco, CA 94114

Work

Position: Professional/Technical

Education

Degree: Graduate or professional degree

Publications

Us Patents

Wd-40-Derived Peptides And Uses Thereof

View page
US Patent:
6342368, Jan 29, 2002
Filed:
Jun 7, 1995
Appl. No.:
08/473089
Inventors:
Dorit Ron - San Francisco CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
C12P 2106
US Classification:
435 691, 4353201, 4352523, 43525411, 435325, 536 231, 536 241
Abstract:
The present invention relates to a polypeptide composition effective to alter the activity of a first protein that interacts with a second protein, where the second protein contains at least one WD-40 region. The polypeptides of the present invention typically have between 4 and 50 amino acids whose sequence is the same as a sequence of the same length in the WD-40 region of the second protein. The invention further includes a method of altering the activity of the above described first protein. In one embodiment of the invention the polypeptide composition is effective to alter the activity of a protein kinase C, where the protein kinase C interacts with a second protein, and the second protein contains at least one WD-40 region (e. g. , RACK1).

Wd-40 Derived Peptides And Uses Thereof

View page
US Patent:
6423684, Jul 23, 2002
Filed:
Jun 7, 1995
Appl. No.:
08/487072
Inventors:
Dorit Ron - San Francisco CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
A61K 3816
US Classification:
514 7, 514 12, 435 4, 435 71, 435 78, 435 15, 435194, 436501, 530300, 530350, 530352
Abstract:
The present invention relates to a polypeptide composition effective to alter the activity of a first protein that interacts with a second protein, where the second protein contains at least one WD-40 region. The polypeptides of the present invention typically have between 4 and 50 amino acids whose sequence is the same as a sequence of the same length in the WD-40 region of the second protein. The invention further includes a method of altering the activity of the above described first protein. In one embodiment of the invention the polypeptide composition is effective to alter the activity of a protein kinase C, where the protein kinase C interacts with a second protein, and the second protein contains at least one WD-40 region (e. g. , RACK1).

Mitigating Symptoms And Behaviors Of Substance Abuse By Modulating Gdnf Or Bdnf Pathway Activity

View page
US Patent:
20050203011, Sep 15, 2005
Filed:
Sep 20, 2004
Appl. No.:
10/946625
Inventors:
Dorit Ron - San Francisco CA, US
International Classification:
C12Q001/68
G01N033/53
G01N033/567
C12Q001/48
A61K038/12
US Classification:
514012000, 435015000, 435007200, 435006000
Abstract:
This invention pertains to the discovery that brain-derived neurotrophic factor (BDNF) and its associated signaling pathway is involved in reversing and/or counteracting neuroadaptations within the mesolimbic system that contribute to the development and/or maintenance of addiction (e.g. alcohol addiction). This invention also pertains to the discovery that ibogaine activity is mediated by changes in mRNA expression of GDNF. Thus, in certain embodiments, this inventioni provides a method of mitigating one or more symptoms of substance abuse in a mammal by increasing the expression or activity of GDNF, BDNF, RACK1, and/or the dopamine D3 receptor (D3R) in said mammal.

Treatment Of Maladaptive Substance Use With H-Ras Antagonists

View page
US Patent:
20070148660, Jun 28, 2007
Filed:
Jun 14, 2006
Appl. No.:
11/453560
Inventors:
Dorit Ron - San Francisco CA, US
International Classification:
C12Q 1/68
G06F 19/00
US Classification:
435006000, 702020000
Abstract:
The present invention provides a method of mitigating a symptom of maladaptive substance use in a subject by inhibiting H-ras. In addition, the invention provides a variety of prescreening and screening methods aimed at identifying agents that modulate a symptom of maladaptive substance use. Methods of the invention can involve assaying test agent binding to H-ras. Alternatively, test agents can be screened for their ability to alter the level of H-ras polypeptides, polynucleotides, or function. Finally, the invention also provides a diagnostic method that entails measuring one or more of these levels and determining risk for maladaptive substance use based on comparison to the corresponding level for a control population.

Methods And Compounds For Treatment Or Prevention Of Substance-Related Disorders

View page
US Patent:
20090258869, Oct 15, 2009
Filed:
Feb 6, 2009
Appl. No.:
12/367412
Inventors:
Dorit RON - San Francisco CA, US
International Classification:
A61K 31/5365
A61K 31/4985
A61K 31/4188
US Classification:
5142295, 514250, 514395
Abstract:
The present disclosure provides methods of treating or preventing a substance-related disorder using Hsp90 inhibitors, Hsp90 modulators, tyrosine hydroxylase modulators, and modulators that reduce the interaction between Hsp90 and tyrosine hydroxylase.

Methods To Identify Immunomodulators Using Cognate Interaction Of Pkc-Theta

View page
US Patent:
59358033, Aug 10, 1999
Filed:
Jun 18, 1996
Appl. No.:
8/665647
Inventors:
Nicki J. Vasquez - San Francisco CA
Dorit Ron - San Francisco CA
Anna F. Voronova - San Bruno CA
Eugene W. Napolitano - San Francisco CA
Assignee:
Terrapin Technologies, Inc. - South San Francisco CA
International Classification:
C12Q 102
C12Q 148
C12Q 168
US Classification:
435 15
Abstract:
Modulators of the immune system can be identified by determining the ability of candidate substances to affect the interaction of PKC-theta or a fragment thereof with its cognate. The interaction can be measured using binding of the cognate as an index, or can be measured using a physiological response.

Wd-40-Derived Peptides And Uses Thereof

View page
US Patent:
55190030, May 21, 1996
Filed:
Feb 1, 1994
Appl. No.:
8/190802
Inventors:
Dorit Ron - San Francisco CA
Assignee:
Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
A61K 3808
C07K 706
US Classification:
514 16
Abstract:
The present invention relates to a polypeptide composition effective to alter the activity of a first protein that interacts with a second protein, where the second protein contains at least one WD-40 region. The polypeptides of the present invention typically have between 4 and 50 amino acids whose sequence is the same as a sequence of the same length in the WD-40 region of the second protein. The invention further includes a method of altering the activity of the above described first protein. In one embodiment of the invention the polypeptide composition is effective to alter the activity of a protein kinase C, where the protein kinase C interacts with a second protein, and the second protein contains at least one WD-40 region (e. g. , RACK1).

Rapid Screening Method For Effectors Of Signal Transduction

View page
US Patent:
57834059, Jul 21, 1998
Filed:
Oct 10, 1995
Appl. No.:
8/541964
Inventors:
Dorit Ron - San Francisco CA
Lawrence M. Kauvar - San Francisco CA
Eugene W. Napolitano - San Francisco CA
Assignee:
Terrapin Technologies, Inc. - San Francisco CA
International Classification:
C12Q 148
C12Q 168
US Classification:
435 15
Abstract:
Methods for assessing libraries of candidate modulators of intracellular signaling transmission pathways are described. The methods assess the ability of candidates from the library to inhibit the binding of peptides which represent participants in the signaling pathways as either a signal-generating protein or its cognate partner binding at a noncatalytic site. Specific peptides useful in this regard have been identified.
Control profile
Dorit Ron from San Francisco, CA, age ~65 Get Report